We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
7.00 | 0.39% | 1,780.50 | 1,778.00 | 1,779.00 | 1,786.50 | 1,771.50 | 1,780.00 | 6,397,670 | 16:35:05 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.86 | 73.22B |
Date | Subject | Author | Discuss |
---|---|---|---|
19/1/2023 15:36 | anhar: Re debt: INCORRECT? How do you work that out? I never gave any figures for debt (he did not ask for it) - he asked for liabilities (and Assets) If you want debt: Its £20B LONG term debt and £3B short-term debt Off-set by £8.5 B cash (eg cash is more than twice short-term debt). Why anyone should be interested in that I dont know. | netcurtains | |
19/1/2023 15:19 | The above figures are incorrect for GSK debt. As at 30.09.22, the latest available, net debt was £18.4bn. This comprised gross debt of £22.1bn less cash and liquid investments of £3.7bn. "Liabilities" is far more than debt because it includes trade creditors etc. | anhar | |
19/1/2023 14:38 | MK19 - If you want the full picture Wall Street Journal gives the full accounts Total Assets £79B total Liabilities £57.7B | netcurtains | |
19/1/2023 14:31 | Yes, HLN has ~£10.8bn | tradermichael | |
19/1/2023 13:52 | More than HLN? Right? | mj19 | |
19/1/2023 12:10 | Total liabilities: ~$60bn | tradermichael | |
19/1/2023 10:10 | How much debt does GSK carry now? | mj19 | |
19/1/2023 09:51 | TM: I must admit I'm quite naive when it comes to GSK. I just look at the share price graph and assume its going up. But nice to have the positive business stuff too. Thanks. | netcurtains | |
19/1/2023 09:03 | Well, I'm always optimistic and especially given the strength of the current pipeline of new entities. In the short term, I'm looking for some positive signs from the Q4 results. | tradermichael | |
18/1/2023 15:05 | Thanks Michael . When do you see a step change upwards in the share price ? | alibizzle | |
18/1/2023 14:36 | Earnings per Share (EPS) is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability. | tradermichael | |
18/1/2023 13:29 | Ah ok , what's EPS? | alibizzle | |
18/1/2023 12:47 | Possible doubts about Q4 earnings. Can this be matched: '21 Q4 EPS beaten by 9% '22 Q1 EPS beaten by 174% '22 Q2 EPS beaten by 16% '22 Q3 EPS beaten by 20% '22 Q4 results due 01 Feb ? | tradermichael | |
18/1/2023 12:08 | Sizeable fall today , possible due to bad forecast from banks about GSK projected sp | alibizzle | |
18/1/2023 09:45 | Morgan Stanley really needs to find something else to say was that worth it?And they never say a reason!!! | mj19 | |
18/1/2023 08:13 | 16 Jan 2023 07:41amGSK : MORGAN STANLEY CUTS TARGET PRICE TO 1520P FROM 1535PThis news story contains no content | mj19 | |
18/1/2023 08:10 | Heading back to the 1300s | spoole5 | |
14/1/2023 10:15 | Do you think after we hopefully have some good news in Florida next month with litigation that share price will start really picking up , or is there another event which may precipitate a step change ( other than a take over ) | alibizzle | |
13/1/2023 13:41 | Good expression . All the analysts such as JP Morgan say at best £15 in 2023 . | alibizzle | |
12/1/2023 15:09 | Rich man's yo yo? | rikky72 | |
12/1/2023 14:54 | What is share doing directionless up in morning and back down in afternoon | mj19 | |
12/1/2023 09:51 | Yes, dividend reached my AJ Bell accounts this morning .... ;0) | tradermichael | |
12/1/2023 09:18 | Divi day today,shares are cheap too. | abdullla |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions